Product logins

Find logins to all Clarivate products below.


Crohn’s Disease and Ulcerative Colitis | TreatmentTrends | EU | 2015

The TreatmentTrends Crohn’s Disease and Ulcerative Colitis (EU) report explores current trends in the management of CD and UC from the perspective of 250 treating EU5 gastroenterologists. The report covers use and patient share of key CD/UC therapies (both biologics and nonbiologics), perceived strengths and weaknesses of the main brands, barriers to broader uptake, brand representative performance, the product attributes that are most important to gastroenterologists, and anticipated uptake of biosimilars and other emerging therapies for these indications.

Related Market Assessment Reports

Report
Ulcerative Colitis – Epidemiology – Epidemiology – Ulcerative Colitis – Mature Markets
Clarivate Epidemiology’s coverage of ulcerative colitis (UC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence…
Report
Crohn’s Disease – Landscape & Forecast – Disease Landscape & Forecast
The Crohn’s disease (CD) therapy market will grow steadily over the next 10 years as a result of the increasing use of biologics and targeted oral therapies. The well-established TNF-α…
Report
Ulcerative Colitis – Access & Reimbursement – Access & Reimbursement – Ulcerative Colitis (US)
TNF-alpha inhibitors (e.g., Johnson & Johnson Innovative Medicine’s Remicade, AbbVie’s Humira) are entrenched in the U.S. ulcerative colitis (UC) therapy market. Alternative treatment options…
Report
Crohn’s Disease – Epidemiology – Epidemiology – Crohn’s Disease – Mature Markets
Clarivate Epidemiology’s coverage of Crohn’s disease (CD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of CD…
Report
Crohn’s Disease – Epidemiology – Epidemiology Dashboard
Clarivate Epidemiology’s coverage of Crohn’s disease comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the total and diagnosed prevalence…